Abiraterone and increased survival in metastatic prostate cancer

N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. doi: 10.1056/NEJMc1107198.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adrenocorticotropic Hormone / blood
  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use*
  • Androstenes
  • Androstenols / adverse effects
  • Androstenols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prednisone / adverse effects
  • Prednisone / therapeutic use*
  • Prostatic Neoplasms / drug therapy*
  • Steroid 17-alpha-Hydroxylase / antagonists & inhibitors*

Substances

  • Androgen Antagonists
  • Androstenes
  • Androstenols
  • Adrenocorticotropic Hormone
  • Steroid 17-alpha-Hydroxylase
  • abiraterone
  • Prednisone